We can’t show the full text here under this license. Use the link below to read it at the source.
SGLT2 Inhibitor and GLP-1 Receptor Agonist Combination Therapy Substantially Improved the Renal Function in a Patient with Type 2 Diabetes: Implications for Additive Renoprotective Effects of the Two Drug Classes
Combined SGLT2 Inhibitor and GLP-1 Receptor Agonist Treatment Strongly Improved Kidney Function in a Type 2 Diabetes Patient, Suggesting Added Kidney Protection
AI simplified
Abstract
At 70 years old, the patient's estimated glomerular filtration rate (eGFR) dropped below 50 mL/min/1.73 m, indicating severe kidney impairment.
- The patient had type 2 diabetes for 16 years and developed macroalbuminuria at age 64.
- Despite maintaining an HbA1c below 7%, the patient's eGFR declined rapidly.
- A renal biopsy confirmed the presence of diabetic nephropathy.
- Combination therapy with sodium glucose transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists led to significant improvements in eGFR and urinary albumin levels.
- The beneficial effects on renal function persisted over a two-year period.
AI simplified